Research programme: cancer therapeutics - Critical Outcome Technologies

Drug Profile

Research programme: cancer therapeutics - Critical Outcome Technologies

Alternative Names: COTI-04; COTI-219; COTI-4A; COTI-58

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Outcome Technologies
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; KRAS protein inhibitors; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Proto oncogene protein c-akt inhibitors; Thymidylate synthase expression modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Small cell lung cancer
  • Research Colorectal cancer

Most Recent Events

  • 28 Aug 2017 Critical Outcome Technologies intends to file an IND application with the US FDA for Cancer (COTI 219) in early 2018
  • 11 Oct 2016 Critical Outcome Technologies announces intention to submit IND to the US FDA in 2017
  • 11 Oct 2016 Pharmacodynamics data from preclinical trials in Small cell lung cancer and Colorectal cancer released by Critical Outcome Technologies (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top